Aminopterin sodium is under clinical development by Syntrix Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Aminopterin sodium’s likelihood of approval (LoA) and phase transition for Plaque Psoriasis (Psoriasis Vulgaris) took place on 18 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Aminopterin sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Aminopterin sodium overview

Aminopterin sodium (aminotrexate) is under development for the treatment of moderate to severe plaque psoriasis. It was also under development for atopic dermatitis, rheumatoid arthritis and pediatric acute lymphocytic leukemia. The drug candidate is administered through the oral route as a tablet and capsule.

Syntrix Pharmaceuticals overview

Syntrix Pharmaceuticals (Syntrix) is a biopharmaceutical company that provides the development and commercialization of therapeutic compounds and research platforms. The company offers various products which include Tramadol, Omnitram, and SX-682. It develops therapies for acute pain, chronic, neuropathic, pulmonary disease, psoriasis, asthma, and other inflammatory diseases including COPD, ulcerative colitis, and cystic fibrosis, among others. Syntrix works in partnership with university researchers, manufacturers and clinical trial teams for its research and development activities. It also develops small molecule solution for multi-resistant bacterial infections. Syntrix is headquartered in Auburn, Washington, the US.

Quick View Aminopterin sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Aminopterin sodium
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.